GO:0042030 ATPase inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042030 ATPase inhibitor activity describes a molecular function in which a protein or small molecule binds to and stops, prevents, or reduces ATP hydrolysis by an ATPase.
• Natural ATPase inhibitor proteins, such as the mitochondrial F1-ATPase inhibitor protein, provide a reversible brake on ATP hydrolysis and are central to energy-conservation mechanisms.
• Small-molecule ATPase inhibitors can selectively target chaperones such as Hsp70/Hsc70 and enhance immune responses to protein antigens.
• ATPase inhibitor activity is not limited to mitochondria; it also regulates bacterial transporters, copper-exporting P1B-type ATPases, and dynamin-like EHD4.
• Experimental approaches to study ATPase inhibitor activity include biochemical ATPase assays, site-directed mutagenesis, and small-molecule screening.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of ATPase inhibitor genes in disease and physiology.
Description
ATPase inhibitor activity (GO:0042030) is a molecular function defined as binding to and stopping, preventing, or reducing an ATP hydrolysis activity. This function is essential for regulating the hundreds of ATPases that consume cellular energy, from mitochondrial F1F0-ATP synthase to bacterial transporters and chaperones. The intrinsic mitochondrial ATPase inhibitor protein was among the first characterized regulators of this class, demonstrating that ATP hydrolysis can be reversibly suppressed to conserve energy under specific metabolic states. Beyond mitochondria, ATPase inhibitor activity extends to bacterial metallo-ATPases such as ArsA, where cysteine residues in the metalloactivation domain coordinate catalytic function and can be targeted by inhibitors. In eukaryotic cells, small molecules that inhibit the ATPase activity of Hsp70 and Hsc70 have been shown to enhance immune responses to protein antigens, illustrating the therapeutic potential of this function. Recent work has also identified drug-like molecules targeting the ATPase activity of dynamin-like EHD4, expanding the scope of ATPase inhibitor activity to membrane trafficking. Understanding GO:0042030 is therefore critical for researchers studying energy metabolism, protein homeostasis, metal transport, and immune modulation.
ATPase inhibitor activity At A Glance
| GO ID | GO:0042030 |
|---|---|
| GO term | ATPase inhibitor activity |
| Ontology | molecular_function |
| Synonym | adenosinetriphosphatase inhibitor |
| Definition | Binds to and stops, prevents or reduces an ATP hydrolysis activity. |
| Major function | Negative regulation of ATP hydrolysis by ATPases |
| Example regulators | Mitochondrial F1-ATPase inhibitor protein, Hsp70/Hsc70 inhibitors, EHD4 inhibitors |
| Related processes | Energy conservation, protein homeostasis, metal transport, immune response |
What Is GO:0042030?
In our own words, ATPase inhibitor activity (GO:0042030) is the function of a molecule that binds to an ATPase enzyme and blocks, reduces, or prevents the hydrolysis of ATP. This activity does not necessarily require the inhibitor to be a protein; small molecules and peptides can also exhibit this function. The QuickGO definition emphasizes binding and inhibition, distinguishing it from ATPase regulators that act indirectly. The synonym adenosinetriphosphatase inhibitor reflects the historical nomenclature for this activity.
Why Is ATPase inhibitor activity Important in Cell Biology?
ATPase inhibitor activity is important because ATP hydrolysis drives countless cellular processes, and its dysregulation contributes to metabolic disorders, cancer, and neurodegeneration. Natural inhibitor proteins such as the mitochondrial F1-ATPase inhibitor prevent wasteful ATP consumption during ischemia or low metabolic demand. Pharmacological ATPase inhibitors targeting Hsp70/Hsc70 can boost antigen-specific immune responses, offering a strategy for vaccine adjuvants or cancer immunotherapy. Inhibitors of copper-exporting P1B-type ATPases have broad-spectrum antimicrobial potential, as these transporters are essential for bacterial metal homeostasis. In addition, inhibitors of dynamin-like EHD4 affect endocytic trafficking, with implications for viral entry and receptor recycling. Thus, GO:0042030 is a focal point for both basic energy biology and therapeutic development.
• Regulates mitochondrial ATP synthase to prevent wasteful ATP hydrolysis under ischemic or low-energy conditions.
• Modulates Hsp70/Hsc70 chaperone activity, influencing protein folding and immune responses to antigens.
• Controls bacterial metal transport via inhibition of P1B-type ATPases, with antimicrobial drug potential.
• Affects membrane trafficking through inhibition of dynamin-like EHD4 ATPase activity.
• Provides a mechanism for fine-tuning ATP-dependent ion pumps and transporters in the brain and other tissues.
• Can be exploited to enhance vaccine efficacy by targeting Hsp70 ATPase activity.
• Involved in the regulation of bacterial ArsA ATPase, a model for metalloactivation and inhibitor design.
• Represents a druggable class of targets for cancer, infectious disease, and neurodegenerative disorders.
Molecular Mechanism of ATPase inhibitor activity
Binding to the ATPase catalytic domain
In simple terms: The inhibitor physically attaches to the ATPase, blocking its ability to break down ATP.
ATPase inhibitor activity begins with binding of the inhibitor to the ATPase, often at or near the catalytic site. For the mitochondrial F1-ATPase, the natural inhibitor protein binds to the F1 sector and prevents ATP hydrolysis without affecting ATP synthesis under certain conditions. In bacterial ArsA, cysteine residues Cys113, Cys172, and Cys422 are in spatial proximity within the metalloactivation domain, and their modification can alter ATPase activity, providing a structural basis for inhibitor interaction. Small-molecule inhibitors of Hsp70/Hsc70 also bind to the ATPase domain and reduce hydrolysis, as shown by enhanced immune responses to protein antigens.
Inhibition of ATP hydrolysis
In simple terms: Once bound, the inhibitor stops the ATPase from using ATP as an energy source.
The functional consequence of ATPase inhibitor activity is a reduction in ATP hydrolysis. For the mitochondrial H+-ATPase, the intrinsic ATPase inhibitor reversibly inhibits H+-ATPase activity, thereby conserving ATP. The interaction of mitochondrial F1-ATPase with its natural inhibitor protein has been characterized biochemically, showing stoichiometric inhibition. In the case of EHD4, drug-like molecules identified through screening inhibit its ATPase activity, affecting dynamin-like function. Similarly, a troponin component TN-I and mitochondrial ATPase inhibitor were shown to inhibit E. coli ATPase activity, demonstrating cross-species inhibition.
Regulation by cofactors and post-translational modifications
In simple terms: Other molecules and chemical changes can turn the inhibitor on or off.
ATPase inhibitor activity can be modulated by cofactors and post-translational modifications. In ArsA, metalloactivation involves cysteine residues that coordinate metal ions, and their spatial arrangement is critical for ATPase function and inhibition. The mitochondrial ATPase inhibitor is sensitive to pH and membrane potential, allowing it to act as a sensor of cellular energy status. Small-molecule inhibitors such as those targeting Hsp70 may compete with nucleotide binding, and their efficacy can be influenced by the presence of co-chaperones. These regulatory layers ensure that ATPase inhibition is context-dependent.
Physiological roles in energy conservation and stress
In simple terms: Inhibiting ATPases helps cells save energy when times are tough.
A major physiological role of ATPase inhibitor activity is energy conservation. During ischemia or low oxygen, the mitochondrial F1-ATPase inhibitor prevents the reverse operation of ATP synthase, avoiding ATP depletion. In bacteria, inhibition of P1B-type ATPases disrupts copper homeostasis, which can be exploited for antimicrobial therapy. In the brain, anion-sensitive Mg2+-ATPase activity is regulated by endogenous inhibitors, contributing to ion homeostasis. These examples highlight how ATPase inhibitor activity integrates metabolic and stress signals.
Pharmacological inhibition and therapeutic implications
In simple terms: Drugs that mimic natural inhibitors can treat diseases.
Pharmacological ATPase inhibitors are being developed for multiple indications. A small molecule inhibitor of Hsp70/Hsc70 ATPase activity enhances the immune response to protein antigens, suggesting use as a vaccine adjuvant. Broad-spectrum inhibitors of copper-exporting P1B-type ATPases have been identified, with potential against bacterial infections. Drug-like molecules targeting EHD4 ATPase activity may modulate endocytic pathways relevant to cancer and infectious disease. These examples demonstrate the translational potential of GO:0042030.
Key Genes Involved in GO:0042030 ATPase inhibitor activity
The following genes and proteins are experimentally linked to ATPase inhibitor activity or serve as key ATPases whose inhibition is studied.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATP5IF1 | Mitochondrial F1-ATPase inhibitor protein | Regulates ATP synthase to prevent ATP hydrolysis during ischemia |
| HSPA1A | Hsp70 ATPase | Target of small-molecule inhibitors that enhance immune responses |
| HSPA8 | Hsc70 ATPase | Inhibited by small molecules to modulate chaperone function |
| EHD4 | Dynamin-like ATPase | Inhibited by drug-like molecules affecting endocytic trafficking |
| ArsA | Bacterial arsenite-translocating ATPase | Model for metalloactivation and inhibitor design |
| ATP7A | Copper-exporting P1B-type ATPase | Target of broad-spectrum inhibitors |
| ATP7B | Copper-exporting P1B-type ATPase | Target of broad-spectrum inhibitors |
| TNNT2 | Troponin T component | TN-I inhibits E. coli ATPase, showing cross-species inhibition |
| ATP1A1 | Na+/K+-ATPase | Anion-sensitive Mg2+-ATPase activity in brain is regulated by inhibitors |
| ATP2A1 | SERCA calcium ATPase | Potential target of ATPase inhibitors in muscle and brain |
| CFTR | ABC transporter ATPase | ATPase inhibitor activity may modulate channel function |
| ABCB1 | P-glycoprotein ATPase | ATPase inhibitors can reverse multidrug resistance |
| KATP | ATP-sensitive potassium channel | ATPase inhibitor activity influences channel gating |
| ATP6V1A | Vacuolar H+-ATPase subunit | Inhibitors can affect lysosomal acidification |
| ATP2B1 | Plasma membrane Ca2+-ATPase | Regulated by endogenous inhibitors in brain |
| ATP12A | Gastric H+/K+-ATPase | Inhibitors used to treat acid-related disorders |
| ATP4A | Gastric H+/K+-ATPase | Inhibitors used to treat acid-related disorders |
How Is ATPase inhibitor activity Regulated?
ATPase inhibitor activity is regulated at multiple levels. The mitochondrial F1-ATPase inhibitor protein is sensitive to pH and membrane potential, allowing it to reversibly inhibit ATP hydrolysis depending on cellular energy status. In bacteria, the ArsA ATPase is regulated by metalloactivation involving cysteine residues, and inhibitors can disrupt this process. Small-molecule inhibitors of Hsp70/Hsc70 compete with nucleotide binding and are influenced by co-chaperones. Additionally, post-translational modifications such as phosphorylation may alter inhibitor binding, though specific pathways remain to be fully defined for many ATPases.
ATPase inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HSPA1A | Cancer, immune evasion | Knockout and point-mutation models to test inhibitor sensitivity |
| ATP5IF1 | Ischemia-reperfusion injury | Knock-in of mutant inhibitor to assess ATP conservation |
| ATP7A | Menkes disease, bacterial infection | Knockout for copper transport and inhibitor testing |
| EHD4 | Endocytic trafficking, viral entry | Overexpression and knockout for drug screening |
| ArsA | Arsenite resistance | Point mutations at cysteine residues to study inhibition |
Cancer and immune modulation
ATPase inhibitor activity is linked to cancer through Hsp70/Hsc70, which are overexpressed in many tumors and promote cell survival. Small-molecule inhibitors of Hsp70/Hsc70 ATPase activity enhance immune responses to protein antigens, suggesting a dual role in cancer immunotherapy. By inhibiting these chaperones, it may be possible to sensitize tumors to immune attack or overcome resistance to apoptosis.
Neurodegeneration and ion homeostasis
In the brain, anion-sensitive Mg2+-ATPase activity is regulated by endogenous inhibitors, and dysregulation of ATPases is implicated in neurodegenerative conditions. Inhibitors of mitochondrial F1-ATPase may protect neurons during ischemia by preventing ATP depletion. Modulating ATPase inhibitor activity could therefore be neuroprotective.
Infectious disease and metal transport
Copper-exporting P1B-type ATPases are essential for bacterial virulence, and broad-spectrum inhibitors of these ATPases have been identified. Inhibiting bacterial ATPases such as ArsA can disrupt arsenite resistance. These findings support the development of ATPase inhibitors as antimicrobial agents.
Metabolic and trafficking disorders
Inhibitors of dynamin-like EHD4 ATPase affect endocytic trafficking, which is relevant to metabolic disorders and viral entry. Additionally, mitochondrial ATPase inhibitor dysfunction may contribute to metabolic syndrome by altering energy expenditure.
From ATPase inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ATPase inhibitor affect energy metabolism? | Knockout of ATP5IF1 in cell lines |
| Can a point mutation in the inhibitor alter binding to ATPase? | Point-mutation knock-in of ATP5IF1 |
| Does overexpression of Hsp70 inhibitor enhance immunity? | Overexpression of dominant-negative Hsp70 |
| How does EHD4 inhibition affect trafficking? | Knock-in of tagged EHD4 for imaging |
| What is the role of ArsA cysteines in inhibition? | Point mutations at Cys113, Cys172, Cys422 |
| Can P1B-ATPase inhibitors be tested in vivo? | Knockout of ATP7A/ATP7B in bacterial models |
How to Study the ATPase inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Malachite green assay | Inorganic phosphate release | Quantify ATPase inhibition |
| ATP/ADP luminescence | ATP hydrolysis rate | Screen inhibitors of Hsp70 |
| Site-directed mutagenesis | Effect of point mutations on inhibition | Map binding sites in ArsA |
| High-throughput screening | Inhibitor potency | Identify EHD4 inhibitors |
| Immunoassays | Antigen-specific immune response | Test Hsp70 inhibitors as adjuvants |
| Fluorescence microscopy | Endocytic trafficking | Assess EHD4 inhibition |
| Copper transport assays | P1B-ATPase function | Test broad-spectrum inhibitors |
| Isothermal titration calorimetry | Binding affinity | Characterize inhibitor-ATPase interaction |
Biochemical ATPase assays
ATPase activity is typically measured by monitoring the release of inorganic phosphate or ADP from ATP. For inhibitor studies, purified ATPase is incubated with candidate inhibitors, and the reduction in hydrolysis is quantified. These assays are foundational for characterizing GO:0042030.
Small-molecule screening
High-throughput screening of chemical libraries can identify drug-like molecules that inhibit ATPase activity. For example, screening identified inhibitors of EHD4 ATPase and Hsp70/Hsc70. These methods enable the discovery of novel pharmacological tools.
Site-directed mutagenesis
Mutating key residues in ATPases or inhibitors can reveal binding interfaces. In ArsA, cysteine-to-alanine mutations at Cys113, Cys172, and Cys422 altered metalloactivation and inhibition. This approach is essential for mechanistic studies.
Cell-based immune and trafficking assays
Inhibitor effects on immune responses can be measured by antigen-specific T-cell proliferation or antibody titers. Trafficking assays using fluorescent cargo can assess EHD4 inhibition. These functional readouts link molecular inhibition to cellular phenotypes.
How CRISPR Can Be Used to Study GO:0042030 ATPase inhibitor activity
Knockout
CRISPR knockout of ATPase inhibitor genes, such as ATP5IF1, can reveal their role in energy metabolism and stress responses. Knockout cells show altered ATP hydrolysis and may be more susceptible to ischemic injury. Similarly, knocking out Hsp70 genes can test the specificity of small-molecule inhibitors.
Point Mutation
Point mutations in ATPase inhibitor genes or in ATPase catalytic domains can dissect binding interfaces. For example, mutating cysteine residues in ArsA (Cys113, Cys172, Cys422) affects metalloactivation and inhibitor sensitivity. CRISPR point-mutation knock-in allows precise modeling of such residues in human cells.
Knock-in
Knock-in of tagged ATPase inhibitors, such as GFP-tagged ATP5IF1, enables live-cell imaging of localization and interactions. Knock-in of disease-associated mutations can model altered inhibitor function in metabolic disorders.
Overexpression
Overexpression of ATPase inhibitors can phenocopy inhibition and test downstream effects. For instance, overexpressing a dominant-negative Hsp70 mutant can mimic small-molecule inhibition and enhance immune responses. Overexpression of EHD4 mutants can probe trafficking defects.
How EDITGENE Supports ATPase inhibitor activity Research
Researchers studying ATPase inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in a specific pathway, disease model, or drug response. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for ATPase inhibitor activity research.
Frequently Asked Questions About ATPase inhibitor activity
What is ATPase inhibitor activity?
ATPase inhibitor activity (GO:0042030) is a molecular function where a molecule binds to and stops, prevents, or reduces ATP hydrolysis by an ATPase.
What genes are involved in ATPase inhibitor activity?
Key genes include ATP5IF1 (mitochondrial F1-ATPase inhibitor), HSPA1A and HSPA8 (Hsp70/Hsc70), EHD4, and bacterial ArsA.
How is ATPase inhibitor activity regulated?
It is regulated by pH, membrane potential, cofactors, and post-translational modifications, as seen for the mitochondrial F1-ATPase inhibitor and ArsA.
What diseases are linked to ATPase inhibitor activity?
It is linked to cancer, ischemia-reperfusion injury, neurodegenerative disorders, and bacterial infections.
What methods study ATPase inhibitor activity?
Biochemical ATPase assays, small-molecule screening, site-directed mutagenesis, and cell-based immune assays are commonly used.
Can CRISPR be used to study ATPase inhibitor activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of ATPase inhibitor genes.
What is the mitochondrial F1-ATPase inhibitor?
It is a natural protein that binds to mitochondrial F1-ATPase and inhibits ATP hydrolysis, conserving energy during ischemia.
Are there small-molecule ATPase inhibitors?
Yes, small molecules inhibiting Hsp70/Hsc70 and EHD4 ATPase activity have been identified and show therapeutic potential.
How does ATPase inhibitor activity affect the immune response?
Inhibiting Hsp70/Hsc70 ATPase activity enhances immune responses to protein antigens, suggesting use as vaccine adjuvants.
What is the role of ATPase inhibitor activity in bacteria?
It can disrupt bacterial metal transport and arsenite resistance, making it a target for antimicrobials.
Conclusion
ATPase inhibitor activity (GO:0042030) is a fundamental molecular function that controls ATP hydrolysis across diverse biological contexts, from mitochondrial energy conservation to immune modulation and bacterial metal transport. Its dysregulation is implicated in cancer, neurodegeneration, and infectious diseases, making it a promising therapeutic target. Continued research using CRISPR models and biochemical assays will further illuminate its mechanisms and translational potential.
References
- 1. Bhattacharjee H et al.. 1996. Spatial proximity of Cys113, Cys172, and Cys422 in the metalloactivation domain of the ArsA ATPase.. J Biol Chem 271(40):24465-70 PMID: 8798705
- 2. Baek KH et al.. 2015. A small molecule inhibitor for ATPase activity of Hsp70 and Hsc70 enhances the immune response to protein antigens.. Sci Rep 5:17642 PMID: 26631605
- 3. Hashimoto T et al.. 1984. [Regulatory mechanism of mitochondrial H+-ATPase (F0F1)--inhibition of H+-ATPase activity by the intrinsic ATPase inhibitor].. Tanpakushitsu Kakusan Koso 29(8):610-21 PMID: 6209746
- 4. De Gómez-Puyou MT et al.. 1980. The interaction of mitochondrial F1-ATPase with the natural ATPase inhibitor protein.. Biochim Biophys Acta 592(3):385-95 PMID: 6448068
- 5. Shanbhag VC et al.. 2026. A broad-spectrum inhibitor of copper-exporting P(1B)-type ATPases.. Proc Natl Acad Sci U S A 123(20):e2604078123 PMID: 42133807
- 6. Mohd S et al.. 2024. Identification of drug-like molecules targeting the ATPase activity of dynamin-like EHD4.. PLoS One 19(7):e0302704 PMID: 39074100
- 7. Inagaki C et al.. 1985. Novel microsomal anion-sensitive Mg2+-ATPase activity in rat brain.. Biochem Pharmacol 34(10):1705-12 PMID: 2988556
- 8. Hagiwara H et al.. 1979. Inhibition of E coli ATPase activity by a troponin component, TN-I, and by mitochondrial ATPase inhibitor.. Experientia 35(12):1558-9 PMID: 160325
